Loring Wolcott & Coolidge Fiduciary Advisors LLP Supernus Pharmaceuticals, Inc. Transaction History

Loring Wolcott & Coolidge Fiduciary Advisors LLP

$11.1 Billion
Q3 2024

2 transactions

Quarter	Operation	Price Per share	shares change	shares Held	SEC Form
Q4 2017 Feb 08, 2018	SELL	$36.4 - $42.6 $1,237 - $1,448	-34 Closed	0 $0
Q3 2017 Oct 27, 2017	BUY	$36.75 - $49.65 $1,249 - $1,688	34	34 $1,000

Others Institutions Holding SUPN

# of Institutions

281

Shares Held

60.6M

Call Options Held

27.7K

Put Options Held

11.3K

Black Rock Inc. New York, NY

10.4M
Shares

$368 Million
0.01% of portfolio
Vanguard Group Inc Valley Forge, PA

6.13M
Shares

$217 Million
0.0% of portfolio
Armistice Capital, LLC New York, NY

5.1M
Shares

$181 Million
2.64% of portfolio
Dimensional Fund Advisors LP Austin, TX

2.88M
Shares

$102 Million
0.02% of portfolio
Macquarie Group LTD Australia, C3

2.63M
Shares

$93.2 Million
0.09% of portfolio

View Full List

About SUPERNUS PHARMACEUTICALS, INC.

Ticker SUPN
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 53,495,300
Market Cap $1.9B
Description
Supernus Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system (CNS) diseases in the United States. Its commercial products are Trokendi XR, an extended release topiramate product indicated for the treatment of epilepsy, as well as for the prop...

More about SUPN

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Loring Wolcott & Coolidge Fiduciary Advisors LLP, based on Form 13F filings with the SEC.

News

Stay updated on Loring Wolcott & Coolidge Fiduciary Advisors LLP with notifications on news.

Account